Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 29INDUSTRY 29NIH 3NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 21Lymphoma 10Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Stomach Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Vinorelbine 4Dexamethasone 4Filgrastim 3Vincristine 2Peripheral Blood Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fenretinide 2Etoposide 2Cytarabine 2Carmustine 2Bortezomib 2zanubrutinib 1relatlimab 1pomalidomide 1pegaspargase 1palbociclib 1liposomal amphotericin B 1ixazomib 1irinotecan sucrosofate 1interferon gamma-1b 1interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1imetelstat 1etoposide phosphate 1elotuzumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Recurrence × Bortezomib × Clear all
NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

European Myeloma Network B.V.

Phase 2 Completed
63 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

European Society for Blood and Marrow Transplantation

Phase 3 Terminated
269 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡